Formosa Laboratories, Inc.

Taiwan Stock Exchange 4746.TW

Formosa Laboratories, Inc. Revenue for the year ending December 31, 2023: USD 142.04 M

Formosa Laboratories, Inc. Revenue is USD 142.04 M for the year ending December 31, 2023, a 15.63% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Formosa Laboratories, Inc. Revenue for the year ending December 31, 2022 was USD 122.83 M, a 8.36% change year over year.
Formosa Laboratories, Inc. Revenue for the year ending December 31, 2021 was USD 113.36 M, a 3.68% change year over year.
Formosa Laboratories, Inc. Revenue for the year ending December 31, 2020 was USD 109.34 M, a 18.52% change year over year.
Formosa Laboratories, Inc. Revenue for the year ending December 31, 2019 was USD 92.25 M, a 4.97% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Taiwan Stock Exchange: 4746.TW

Formosa Laboratories, Inc.

CEO	Dr. Chen-Yu Cheng Ph.D.
IPO Date	Feb. 28, 2011
Location	Taiwan
Headquarters	36 Hoping Street
Employees	867
Sector	Health Care
Industries Pharmaceuticals

Description

Formosa Laboratories, Inc. produces and sells active pharmaceutical ingredients (APIs) worldwide. The company offers APIs in the areas of anticancer, anti-inflammatory and analgesic agents, MRI enhancing agents, cholesterol and phosphate binders, CNS agents, immunomodulators, respiratory agents, steroids, vitamin D derivatives, and antibiotics. It also provides contract development and manufacturing services; solutions for manufacturing antibody-drug conjugates; and injectable manufacturing services. The company was founded in 1995 and is based in Taoyuan City, Taiwan.

Key trends

Past 5 years